No don't know about 20@, but I do know that this company should be at 15 right now, or about 1.2 billion market cap, given the potential of imelestat.
Just to add to what itsupfromhere says, most institutional ownership doesn't come from the float. They are either allocated shares from the IPO (to make the book), or from shelf placements, or from secondary offerings. But they'll buy from the open market if the price is right, and if the float is large enough for the price to hold up in a sale (unless their intent is to manipulate the price buy manipulating a small float)
This deal will get done. Shire has gone hostile on Baxalta, and Baxalta doesn't have the time to start this process over on another company. They'll pay a few hundred to get it done in order to derail Shire.
Can you please post a link that documents this? Thank you!
"The FACT that the co-therapy of SD-101 and a PD-1 inhibitor resulted in a PERFECT 100% SURVIVAL and 100% COMPLETE REMISSIONS in pre-clinical studies against melanoma..."
Hey, bourbon on cornflakes may be gross, but bourbon definitely knows his Swiss. I spent years 13-16 in a Swiss boarding school in Fribourg (not Freiburg, which is in Germany, mind you), and those are indeed the four languages the Swiss speak...well... You can make it five and a half, because most Swiss speak English, and most speak both proper German as well as their Switze-Deutch (which I may have misspelled! But back to AVXL. I'm sure I'm not the only one that was in PRAN, or a myriad of other names that have failed in AD. Nonetheless, I'm intrigued with the synergy between Donepezil and 2-73, even though it didn't work with memantine (two different mechanisms of action). Both are $2 billion drugs, roughly speaking, but NIH says Donepezil is slightly more cost-effective, so if the 4x 2-73+Donepezil scores hold up over Donepezil alone, we are in big business. But as I've suggested, this is highly speculative stuff, so make sure you know what your #$%$ looks like so you know what you'd be losing, just in case. ;-)
Igonber, Kwantung: there's nothing unusual for GILD. Down 15%, CELG down 14.6%, REGN down 15%, NBI index down 15%. The big caps are following the index. Igonber, fyi I got out of BLUE in the $165-170 range. JUNO at $54. KITE in the 60s. I have found myself in a series of microcaps now. Many of them seem to fly under the radar during carnage like this.
and did you see how it handled Aug 21st's 110 point drop in the NBI and 530 Drop in the Dow? Up $1.02. $15-$18 is the place to be accumulating this, not dumping it!!!
I'm in this as well. Just 10,000 shares, but I suspect the remainder of the 2A results for 2-73 will also be positive, which should push this up another few bucks. It's not a cure for AD, but it's showing some early promising results based on biomarkers. The AD space is littered with a hundred failed trials, and this one could prove to be no different, but if it works in a larger trial, watch out!
that qualifies as a callous, cynical post. It's time to cover your short - do you see how AQXP is behaving in the face of a very down day today?
In case you didn't figure it out, these are the beginning lyrics of "Midnight Rider", Allman Brothers 1970, album was Idlewild. I took the liberty of replacing "rider" with "trader". I think it works nicely! My apologies to Gregg Allman was listed by Rolling Stone Magazine as one of the 100 Greatest Singers of All Time."